Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as complementary to its top-selling product, the blockbuster inflammatory bowel disorder drug Entyvio, and competitive against Bristol Myers Squibb's Sotyktu.
https://medcitynews.com/2023/03/tak...that-led-to-a-4b-deal-for-an-autoimmune-drug/
https://medcitynews.com/2023/03/tak...that-led-to-a-4b-deal-for-an-autoimmune-drug/
